Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D C Talbot

Showing results (41-50 of 65) with videos related to

Pageof 7
Sort By:
British Journal of Cancer|May 1, 1996
Modulation of bryostatin 1 muscle toxicity by nifedipine: effects on muscle metabolism and oxygen supplyC H Thompson, V M Macaulay, K J O'Byrne, et al.
Journal of the National Cancer Institute|November 17, 1993
Phase I study of bryostatin 1: assessment of interleukin 6 and tumor necrosis factor alpha induction in vivo. The Cancer Research Campaign Phase I CommitteeP A Philip, D Rea, P Thavasu, et al.
British Journal of Cancer|June 6, 2000
Phase II study of second-line therapy with DTIC, BCNU, cisplatin and tamoxifen (Dartmouth regimen) chemotherapy in patients with malignant melanoma previously treated with dacarbazineD J Propper, J P Braybrooke, N C Levitt, et al.
British Journal of Cancer|October 2, 2003
Comparison of prognostic factors in patients in phase I trials of cytotoxic drugs vs new noncytotoxic agentsC Han, J P Braybrooke, G Deplanque, et al.
Anti-Cancer Drugs|December 1, 1995
Combination chemotherapy with gemcitabine and cisplatin in the treatment of advanced non-small cell lung cancer: preliminary results of an ongoing phase I/II studyW P Steward, D J Dunlop, C Cameron, et al.
Cancer Chemotherapy and Pharmacology|February 9, 2000
Evaluation of the alkaline comet assay and urinary 3-methyladenine excretion for monitoring DNA damage in melanoma patients treated with dacarbazine and tamoxifenJ P Braybrooke, S Houlbrook, J E Crawley, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 1, 1999
Phase I study of intrapleural batimastat (BB-94), a matrix metalloproteinase inhibitor, in the treatment of malignant pleural effusionsV M Macaulay, K J O'Byrne, M P Saunders, et al.
British Journal of Cancer|July 17, 1998
Cyclophosphamide, methotrexate and infusional 5-fluorouracil (infusional CMF) in metastatic breast cancerK J O'Byrne, M I Koukourakis, M P Saunders, et al.
British Journal of Cancer|April 3, 1999
Phase II study of RC-160 (vapreotide), an octapeptide analogue of somatostatin, in the treatment of metastatic breast cancerK J O'Byrne, N Dobbs, D J Propper, et al.
British Journal of Cancer|July 17, 1998
Phase I study of the mitomycin C analogue BMS-181174V M Macaulay, K J O'Byrne, J A Green, et al.
Pageof 7

Showing results (41-50 of 65) with videos related to

Sort By:
Pageof 7
British Journal of Cancer|May 1, 1996
Modulation of bryostatin 1 muscle toxicity by nifedipine: effects on muscle metabolism and oxygen supplyC H Thompson, V M Macaulay, K J O'Byrne, et al.
Journal of the National Cancer Institute|November 17, 1993
Phase I study of bryostatin 1: assessment of interleukin 6 and tumor necrosis factor alpha induction in vivo. The Cancer Research Campaign Phase I CommitteeP A Philip, D Rea, P Thavasu, et al.
British Journal of Cancer|June 6, 2000
Phase II study of second-line therapy with DTIC, BCNU, cisplatin and tamoxifen (Dartmouth regimen) chemotherapy in patients with malignant melanoma previously treated with dacarbazineD J Propper, J P Braybrooke, N C Levitt, et al.
British Journal of Cancer|October 2, 2003
Comparison of prognostic factors in patients in phase I trials of cytotoxic drugs vs new noncytotoxic agentsC Han, J P Braybrooke, G Deplanque, et al.
Anti-Cancer Drugs|December 1, 1995
Combination chemotherapy with gemcitabine and cisplatin in the treatment of advanced non-small cell lung cancer: preliminary results of an ongoing phase I/II studyW P Steward, D J Dunlop, C Cameron, et al.
Cancer Chemotherapy and Pharmacology|February 9, 2000
Evaluation of the alkaline comet assay and urinary 3-methyladenine excretion for monitoring DNA damage in melanoma patients treated with dacarbazine and tamoxifenJ P Braybrooke, S Houlbrook, J E Crawley, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 1, 1999
Phase I study of intrapleural batimastat (BB-94), a matrix metalloproteinase inhibitor, in the treatment of malignant pleural effusionsV M Macaulay, K J O'Byrne, M P Saunders, et al.
British Journal of Cancer|July 17, 1998
Cyclophosphamide, methotrexate and infusional 5-fluorouracil (infusional CMF) in metastatic breast cancerK J O'Byrne, M I Koukourakis, M P Saunders, et al.
British Journal of Cancer|April 3, 1999
Phase II study of RC-160 (vapreotide), an octapeptide analogue of somatostatin, in the treatment of metastatic breast cancerK J O'Byrne, N Dobbs, D J Propper, et al.
British Journal of Cancer|July 17, 1998
Phase I study of the mitomycin C analogue BMS-181174V M Macaulay, K J O'Byrne, J A Green, et al.
Pageof 7